Blocking ET-1 receptors does not correct subnormal retinal oxygenation response in experimental diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 8, 2006, Pages 3550-3555

  Roberts, Robin ^a   Luan, Hongmei ^a   Berkowitz, Bruce A ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APYRASE; BOSENTAN; CARBOGEN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; OXYGEN; SULFONAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; HISTOPATHOLOGY; IMAGE ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; OXYGEN CONSUMPTION; PATHOLOGY; PRESSURE; RETINA; RETINA BLOOD VESSEL;

ANIMALS; APYRASE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ENDOTHELIN-1; MAGNETIC RESONANCE IMAGING; OXYGEN; OXYGEN CONSUMPTION; PARTIAL PRESSURE; RATS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RETINA; RETINAL VESSELS; SULFONAMIDES;

EID: 33748112823     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.05-1624     Document Type: Article

References (39)

1. Deng D, Evans T, Mukherjee K, Downey D, Chakrabarti S. Diabetes-induced vascular dysfunction in the retina: role of endothelins. Diabetologia. 199942:1228-1234.
2. Takagi C, Bursell SE, Lin YW, et al. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci. 1996;37:2504-2518.
3. Chakravarthy U, Hayes RG, Stitt AW, Douglas A. Endothelin expression in ocular tissues of diabetic and insulin-treated rats. Invest Ophthalmol Vis Sci. 1997;38:2144-2151.
4. Takagi C, King GL, Takagi H, Lin YW, Clermont AC, Bursell SE. Endothelin-1 action via endothelin receptors is a primary mechanism modulating retinal circulatory response to hyperoxia. Invest Ophthalmol Vis Sci. 1996;37:2099-2109.
5. Trick GL, Berkowitz BA. Retinal oxygenation response and retinopathy. Prog Retin Eye Res. 2005;24:259-274.
6. Yu DY, Cringle SJ, Alder V, Su EN. Intraretinal oxygen distribution in the rat with graded systemic hyperoxia and hypercapnia. Invest Ophthalmol Vis Sci. 1999;40:2082-2087.
7. 2. Invest Ophthalmol Vis Sci. 2004;45:3669-3677.
8. Kowluru RA, Engerman RL, Kern TS. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII: prevention by aminoguanidine. Curr Eye Res. 2000;21:814-819.
9. Berkowitz BA, Ito Y, Kern TS, McDonald C, Hawkins R. Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 2001;42:2964-2969.
10. Park JY, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes. 2000;49:1239-1248.
11. Berkowitz BA, Luan H, Gupta RR, et al. Regulation of the early subnormal retinal oxygenation response in experimental diabetes by inducible nitric oxide synthase. Diabetes. 2004;53:173-178.
12. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270:228-235.
13. Cosenzi A, Bernobich E, Plazzotta N, Seculin P, Bellini G. Bosentan reduces blood pressure and the target-organ damage induced by a high-fructose diet in rats. J Hypertens. 1999;17:1843-1848.
14. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, Clozel M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol. 2003;42:48-54.
15. Arikawa E, Verma S, Dumont AS, McNeill JH. Chronic bosentan treatment improves renal artery vascular function in diabetes. J Hypertens. 2001;19:803-812.
16. Chen S, Khan ZA, Cukiernik M, Chakrabarti S. Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. Am J Physiol. 2003;284:E1089-E1097.
17. Evans T, Deng DX, Chen S, Chakrabarti S. Endothelin receptor blockade prevents augmented extracellular matrix component mRNA expression and capillary basement membrane thickening in the retina of diabetic and galactose-fed rats. Diabetes. 2000;49:662-666.
18. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol. 1996;271:H88-H93.
19. Berkowitz BA, Zhang W. Significant reduction of the panretinal oxygenation response after 28% supplemental oxygen recovery in experimental ROP. Invest Ophthalmol Vis Sci. 2000;41:1925-1931.
20. Lutty GA, McLeod DS. A new technique for visualization of the human retinal vasculature. Arch Ophthalmol. 1992;110:267-276.
21. Brain SD. The direct observation of arteriolar constriction induced by endothelin in vivo. Eur J Pharmacol. 1989;160:401-403.
22. Bursell SE, Clermont AC, Oren B, King GL. The in vivo effect of endothelins on retinal circulation in nondiabetic and diabetic rats. Invest Ophthalmol Vis Sci. 1995;36:596-607.
23. Berkowitz BA. Adult and newborn rat inner retinal oxygenation during carbogen and 100% oxygen breathing: comparison using magnetic resonance imaging delta PO2 mapping. Invest Ophthalmol Vis Sci. 1996;37:2089-2098.
24. Berkowitz BA. Role of dissolved plasma oxygen in hyperoxia-induced contrast. Magn Reson Imag. 1997;15:123-126.
25. Berkowitz BA. The role of dissolved plasma oxygen in hyperoxia induced contrast. Magn Reson Imaging. 1995;15:123-126.
26. Tofts PS, Berkowitz BA. Rapid measurement of capillary permeability using the early part of the dynamic Gd-DTPA MRI enhancement curve. J Magn Reson. 1993;102:129-136.
27. Ettl A, Fischer-Klein C, Chemelli A, Daxer A, Felber S. Proton relaxation times of the vitreous body in hereditary vitreoretinal dystrophy. Ophthalmologica. 1994;208:195-197.
28. Hopkins AL, Yeung HN, Bratton CB. Multiple field strength in vivo T1 and T2 for cerebrospinal fluid protons. Magn Reson Med. 1986;3:303-311.
29. Luoma K, Raininko R, Nummi P, Luukkonen R. Is the signal intensity of cerebrospinal fluid constant? - intensity measurements with high and low field magnetic resonance imagers. Magn Reson Imaging. 1993;11:549-555.
30. Meyer ME, Yu O, Eclancher B, Grucker D, Chambron J. NMR relaxation rates and blood oxygenation level. Magn Reson Med. 1995;34:234-241.
31. Alder VA, Yu DY, Cringle SJ. Vitreal oxygen tension measurements in the rat eye. Exp Eye Res. 1991;52:293-299.
32. Liang Z. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22.
33. Chakrabarti S, Cukiernik M, Hileeto D, Evans T, Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev. 2000;16:393-407.
34. Evans T, Xi DD, Mukherjee K, Downey D, Chakrabarti S. Endothelins, their receptors, and retinal vascular dysfunction in galactose-fed rats. Diabetes Res Clin Pract. 2000;48:75-85.
35. Ahmed J, Pulfer MK, Linsenmeier RA. Measurement of blood flow through the retinal circulation of the cat during normoxia and hypoxemia using fluorescent microspheres. Microvasc Res. 2001;62:143-153.
36. Linsenmeier RA, Braun RD. Oxygen distribution and consumption in the cat retina during normoxia and hypoxemia. J Gen Physiol. 1992;99:177-197.
37. Yamamoto F, Steinberg RH. Effects of systemic hypoxia on pH outside rod photoreceptors in the cat retina. Exp Eye Res. 1992;54:699-709.
38. Berkowitz BA, Roberts R, Luan H, et al. Drug intervention can correct subnormal retinal oxygenation response in experimental diabetic retinopathy. Invest Ophthalmol Vis Sci. 2005;46:2954-2960.
39. Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia. 1999;42:387-405.